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We are not doing too well with the prescribing of medicines in Britain. A recent review of the best evidence for the Royal Pharmaceutical Society of Great Britain (RPSGB) 1 found errors at each step of medicines use. There is an error rate of 7.5% in primary care prescribing, 2.6-5.2% of prescriptions are not taken to the pharmacy, and 3.3% of prescriptions are incorrectly dispensed. Non-adherence by patients with a chronic condition is 30-50%, and 72% of medicines are not reviewed for more than a year. Around 4-5% of hospital admissions are due to avoidable adverse events from medicines. On admission 58% of patients have discrepancies in their medicines and the inpatient prescribing error is 1.5-9.2%. After discharge and a subsequent prescription, around half of patients have unintentional discrepancies in their medicines. Following outpatient visits, 5% of prescribed items are not added to the general practitioners' records and doses are not recorded in 13% of consultations. 1 Access to medicines is another issue; it is heavily controlled by regulation. Patients may suffer unnecessarily, or go long periods without treatment because they cannot get to a doctor who can write them the prescription they require.
The question is, could we improve prescribing quality and access for patients by extending prescribing rights to other professional groups -or would it make matters worse?
In answering this, we need first to differentiate, as has been done in the UK, between prescribing that follows a diagnosis and agreed clinical management plan (called, unhelpfully, supplementary prescribing in the UK) and the combined act of diagnosis and prescribing (called independent prescribing in the UK).
The drive to extend prescribing rights in the UK came predominantly from nurses. They conducted a large, politically adept campaign which was aided by the public's perceptions of of such variability which is quite impressive considering that for most drugs, 100% of the dose variability cannot be explained. It is very unlikely that additional genetic factors will be uncovered, as whole genome association studies have clearly identified CYP2C9 and VKORC1 genotype as the major genetic contributors to dosage requirements with a very small contribution by CYP4F2. 1 Other factors that need to be considered are drug-drug interactions, medication adherence, psychosocial factors and the less than optimal system of care for people prescribed warfarin. 2 The Food and Drug Administration in the US refers to the genetic factors (CYP2C9 and VKORC1) which influence dosage requirements in the product information for warfarin, but
Medicare and Medicaid will not pay for the genetic test (except as part of clinical trials) because of insufficient evidence of benefit. There is clearly a need for large scale prospective studies, including pharmacoeconomic studies, before any decisions are made to incorporate genetic testing into best practice guidelines. 3 In Australia, the situation is complex as some pathology services already advertise the test, but there are no known large prospective multicentre trials being conducted to determine feasibility, interpretation, dosage recommendations and cost-benefit. It is timely that this be done so that Australia, with its different spread of ethnicities and diets, can contribute to the evidence and importantly, that Australian-based costbenefit analyses and dosage recommendations can be made to determine whether or not warfarin genetic testing should become part of treatment guidelines.
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